Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vivos Therapeutics, Inc. on April 15, 2026. The filing serves to announce the Company's financial results for the fiscal year ended December 31, 2025. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document explicitly states that the full financial results are included in the attached press release (Exhibit 99.1) and are not detailed within the body of this Form 8-K.
Material Changes
No material changes versus the prior comparable period are described in the text of this filing. The document acts solely as a notification of the release of the annual results.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It includes a standard disclaimer stating that the information in this report and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the fiscal year ended December 31, 2025.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full announcement.
- Confirm the status of any outstanding debt or financing arrangements detailed in the full financial report.